Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT06234605

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Led by HiberCell, Inc. · Updated on 2026-01-15

80

Participants Needed

20

Research Sites

183 weeks

Total Duration

On this page

Sponsors

H

HiberCell, Inc.

Lead Sponsor

M

Merck Sharp & Dohme LLC

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combination dose expansion). The primary purpose of this study is to determine the maximum tolerated dose of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene mutation status.

CONDITIONS

Official Title

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of locally advanced (inoperable) or metastatic renal cell carcinoma with a predominant clear cell component
  • Age 18 years or older (male or female) at the time of consent
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 20 locations

1

University of Arizona Cancer Center

Tucson, Arizona, United States, 85719

Actively Recruiting

2

University of California San Diego Moores Cancer Center

La Jolla, California, United States, 92093

Actively Recruiting

3

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048

Actively Recruiting

4

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States, 80045

Actively Recruiting

5

Rocky Mountain Cancer Centers, LLP

Lone Tree, Colorado, United States, 80124

Actively Recruiting

6

Yale - New Haven Hospital

New Haven, Connecticut, United States, 06520

Actively Recruiting

7

HealthPartners Cancer Research Center

Saint Paul, Minnesota, United States, 55101

Actively Recruiting

8

Washington University School of Medicine

St Louis, Missouri, United States, 63110

Actively Recruiting

9

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

Actively Recruiting

10

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States, 44106

Actively Recruiting

11

Cleveland Clinic

Cleveland, Ohio, United States, 44195

Actively Recruiting

12

Providence Cancer Institute

Portland, Oregon, United States, 97213

Actively Recruiting

13

SCRI Oncology Partners

Nashville, Tennessee, United States, 37203

Actively Recruiting

14

Texas Oncology

Dallas, Texas, United States, 75246

Actively Recruiting

15

University of Texas Southwestern Medical Center

Dallas, Texas, United States, 75390

Actively Recruiting

16

University Medical Center & Texas Tech Health Science Center

Lubbock, Texas, United States, 79430

Actively Recruiting

17

Virginia Cancer Specialists

Fairfax, Virginia, United States, 22031

Actively Recruiting

18

Swedish Medical Center

Seattle, Washington, United States, 98104

Actively Recruiting

19

Fred Hutchinson Cancer Center

Seattle, Washington, United States, 98109

Actively Recruiting

20

University of Wisconsin - Carbone Cancer Center

Madison, Wisconsin, United States, 53705

Actively Recruiting

Loading map...

Research Team

M

Michele Gargano

CONTACT

P

Paulette Mattson

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma | DecenTrialz